Investigators concluded that a baseline PSA of 3 ng/mL is an appropriate minimum cutoff
"In a population-based screening study of nearly 20,000 men in Rotterdam, men with baseline prostate-specific antigen (PSA) levels < 3 ng/mL were at very low risk of developing prostate cancer. Investigators concluded that a baseline PSA of 3 ng/mL is an appropriate minimum cutoff for determining the need for biopsy and that longer intervals between PSA screening may be possible in this group.
The results were presented at the 2011 Genitourinary Cancers Symposium, in Orlando, Florida, by lead investigator Monique Roobol, PhD, an epidemiologist from Erasmus University Medical Center in Rotterdam (Bul et al, abstract 7). The Rotterdam study is part of the European Randomised Study of Screening for Prostate Cancer (ERSPC), a randomized controlled trial running in eight European countries (Belgium, Finland, France, Italy, The Netherlands, Spain, Sweden, and Switzerland)."
I am more interested in the ultrasensitive troponin assay. Heart attacks and false heart attacks are the #1 cause of ER visits and overnight stays.
Regardless, it looks to me that you might be in trouble. The attempt to break 3.10 kind of hit a wall, so to speak. Now, NSPH is at 90K share and close to even on the day. Why don't you short another 100K and see how that goes?
Sounds like some desparation on both sides of the argument to be honest. The technical side vs commerical need (which is not clearly established for all of Nanosphere's assays). Sammy is nervous though. I'd be a liar if I were to say I was calm, cool and collected myself.
WORDS do not matter at this point. The DOW is down TRIPLE DIGITS and you need to get NSPH to BREAK below $3.10. TODAY would be the day. You are going to need to throw some MONEY AT IT. Are you up to the task??????????